KDR and cancer: In addition to proteinaceous biological tools targeting VEGFR2 or the bioavailability of its ligands, strategies for inhibiting the activity of angiogenic receptor tyrosine kinases (RTKIs) at the catalytic domain in a competitive or allosteric way have evolved as systemic treatment modalities for cancer (Table 1; Figure 2 and Figure 3) [17,228,260].